Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GeneDx Holdings (WGS) Operating Expenses (2020 - 2025)

Historic Operating Expenses for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to $64.3 million.

  • GeneDx Holdings' Operating Expenses rose 6656.65% to $64.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $187.8 million, marking a year-over-year increase of 2570.39%. This contributed to the annual value of $146.8 million for FY2024, which is 2353.34% down from last year.
  • GeneDx Holdings' Operating Expenses amounted to $64.3 million in Q3 2025, which was up 6656.65% from $42.5 million recorded in Q2 2025.
  • GeneDx Holdings' Operating Expenses' 5-year high stood at $155.2 million during Q1 2021, with a 5-year trough of $24.8 million in Q2 2021.
  • Over the past 5 years, GeneDx Holdings' median Operating Expenses value was $51.0 million (recorded in 2021), while the average stood at $58.1 million.
  • The largest annual percentage gain for GeneDx Holdings' Operating Expenses in the last 5 years was 29679.72% (2022), contrasted with its biggest fall of 5616.64% (2022).
  • Over the past 5 years, GeneDx Holdings' Operating Expenses (Quarter) stood at $80.2 million in 2021, then dropped by 15.74% to $67.6 million in 2022, then plummeted by 42.47% to $38.9 million in 2023, then fell by 6.58% to $36.3 million in 2024, then surged by 76.97% to $64.3 million in 2025.
  • Its Operating Expenses stands at $64.3 million for Q3 2025, versus $42.5 million for Q2 2025 and $44.7 million for Q1 2025.